COCPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cocrystal Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.95−0.07 (-7.20%)
Close on Oct 19, 2026
- Market cap
- $13.05M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.1234 (−11.53%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $13.05M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 12.50
- Dividend yield
- –
- Free cash flow yield
- -62.86%
Fundamentals
- Net income
- -$9.94M
- EPS, diluted
- -$0.77
- Free cash flow
- -$8.20M
- Book value per share
- $0.08
- Diluted shares
- 14M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$10.11M
Net income
-$9.94M
EPS, diluted
-$0.77
Free cash flow
–
Reported periodTrailing twelve months